{
  "intro": {
    "heading": "Consider including <b><i>KRAS G12C</i></b>—the most prevalent emerging biomarker—in your NSCLC biomarker panels<sup class='sup osup'>4,5</sup>",
    "text3":"Follow guidelines. <br class='mobile-show' style='display:none;'>Test for <i>KRAS G12C</i>.",
    "text4": "Includes patients with advanced/metastatic NSCLC, but not locally advanced NSCLC.",
    "text5": "It is recommended at this time that when feasible, molecular testing be performed via a broad, panel-based approach, most typically performed by NGS.",
    "text6": "The NCCN Guidelines<sup class='sup osup'>®</sup> recommend molecular testing in eligible patients with advanced/metastatic NSCLC and strongly advise broader molecular profiling to identify rare driver mutations for which effective therapy may already be available.",
    "text7": "The NCCN Guidelines<sup class='sup osup'>®</sup> for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays.",
    "text8": "<i>ALK,</i> anaplastic lymphoma kinase; AMP, Association for Molecular Pathology; ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; <i>EGFR,</i> epidermal growth factor receptor; IASLC, International Association for the Study of Lung Cancer; <i>KRAS,</i> Kirsten rat sarcoma; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; <i>ROS1,</i> ROS proto-oncogene 1, receptor tyrosine kinase.",
    "text9": "<b>References: 1.</b> Kalemkerian GP, et al. <i>J Clin Oncol.</i> <span class='lineblue'>2018;36(9):911-919.</span> <b>2.</b> Lindeman NI, et al. <i>Arch Pathol Lab Med.</i> <span class='lineblue' style='white-space: nowrap;'>2018;142(3):321-346.</span> <b>3.</b> Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup class='sup osup'>®</sup>) for Non-Small Cell Lung Cancer <span class='lineblue'>v.8.2020.</span> © National Comprehensive Cancer Network, Inc. <span class='lineblue'>2020.</span> All rights reserved. Accessed <span class='lineblue'>September 22, 2020.</span> To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. <b>4.</b> Data on file, Amgen; 2020. <b>5.</b> Pennell NA, et al. <i>Am Soc Clin Oncol Educ Book.</i> <span class='lineblue'>2019;39:531-542.</span>",
    "text10": "One Amgen Center Drive, <br class='mobile-show' style='display:none;'>Thousand Oaks, CA 91320-1799",
    "text11": "© 2020 Amgen Inc. All rights reserved. <br class='mobile-show' style='display:none;'><span class='lineblue'>USA-510-80169 11/20</span>",
    "text12": "If you prefer not to receive further messages from this center, please click here and confirm your request."
  }
  }
